Finding new drugs to reduce harmful lipid buildup in Alzheimer's disease linked to APOE4.
Official title: High-Content Screen to Identify Small Molecule Therapeutics that Reduce Aberrant Lipid Accumulation in APOE4 Alzheimer's Disease
Funded at Mcm6 Therapeutics, INC. · NIH-11067722 · Data updated 2026-11-12
This study is looking at how a specific gene linked to Alzheimer's disease affects fat processing in the brain, and it's trying to find new medications that could help keep brain cells healthy by reducing harmful fat buildup, which could lead to better treatment options for people with Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mcm6 Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $473,216 |
| NIH project number | 1R41AG087802-01A1 |
| Project ID | NIH-11067722 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a genetic predisposition to Alzheimer's disease, particularly those carrying the APOE4 allele.
✕Less likely to help
Patients without the APOE4 allele or those with other forms of dementia unrelated to lipid metabolism may not benefit from this research.
What this research studies
This research focuses on understanding how the APOE4 gene, which significantly increases the risk of Alzheimer's disease, affects lipid metabolism in the brain. By using advanced cell models, the team aims to identify small molecule therapeutics that can reduce the harmful accumulation of lipids in oligodendrocytes, the cells responsible for myelinating and protecting neurons. The approach involves high-content screening to discover potential drugs that can restore normal lipid levels and improve brain health. Patients may benefit from new treatment options that specifically target the underlying mechanisms of Alzheimer's disease related to lipid dysregulation.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically address lipid accumulation in Alzheimer's patients, potentially slowing disease progression.
How similar studies have gone: While the specific approach of targeting lipid accumulation in APOE4-related Alzheimer's is novel, similar strategies targeting lipid metabolism have shown promise in other neurological conditions.
Where this research is happening
-
Mcm6 Therapeutics, INC.
Lexington, United States Active
Researchers
- Principal investigator: Lam, Kelvin T — Mcm6 Therapeutics, INC.
- Study coordinator: Lam, Kelvin T
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.